Prostate Cancer Research
To learn more about prostate cancer and ongoing clinical trials in this area, visit our Prostate Cancer Research page.
Prostate Cancer ResearchThe purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse.
Participant must have prostate cancer that has spread to other parts of the body and is expected to respond to hormone treatments designed to lower testosterone (metastatic hormone-sensitive prostate cancer)
Participant must have cancer that has spread to the bones significantly and/or to the viscera, which are the soft internal organs of the body (for example, the lungs, liver, and the organs of the digestive system)
Participant must have adequate organ function
Participant must not have received prior treatment with abemaciclib or other drugs that work in the same way
Participant must not have received previous treatment(s) for metastatic cancer except for up to 3 months of androgen deprivation therapy (ADT) or up to 6 courses of chemotherapy with ADT
Participant must not have serious or uncontrolled medical conditions such as certain cardiovascular disorders, active or chronic liver disease, uncontrolled hypertension, active systemic infections or currently treated for cancer other than prostate
Participant must not have prostate cancer that has spread to the central nervous system that is not treated and stable
To learn more about prostate cancer and ongoing clinical trials in this area, visit our Prostate Cancer Research page.
Prostate Cancer ResearchTo learn more about the different types of cancer research we conduct and ongoing clinical trials, visit our Cancer Research page.
Learn MoreA clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.